PeerView Oncology
Targeting DNA Repair Defects Through PARPi in mPC: Why Are Somatic/Germline Alterations Important? How Can We Selectively Stop BRCA-Mutated Disease? Do BRCA 2 Carriers Have Worse Prognosis? What Are the Current NCCN Testing Guidelines?
By
PeerView Oncology
FEATURING
Emmanuel Antonarakis
By
PeerView Oncology
FEATURING
Emmanuel Antonarakis
Comments 0
Login to view comments.
Click here to Login